CA-ENCHROMA
14.12.2022 08:01:37 CET | Business Wire | Press release
The Centre Pompidou today announced that colour blind visitors are now able to borrow EnChroma glasses for colour blindness during visits to the iconic museum. The Centre Pompidou is internationally renowned for its collection of modern and contemporary art totaling over 120,000 works – the most extensive in all of Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213006029/en/
Robert Delaunay, Manège de cochons, 1922. Don de Mme Sonia Delaunay en 1956. Centre Pompidou, Paris, Musée national d’art moderne - Centre de création industrielle. Colour blind view courtesy of EnChroma. (Graphic: Business Wire)
One in twelve men (8%) and one in 200 women (0.5%) are colour blind – about 2.8 million in France, 30 million in Europe and 350 million globally. With over three million annual visitors, an estimated 128,000 guests to the Centre Pompidou are colour blind. EnChroma glasses will enable colour blind visitors to perceive an expanded range of clear, vibrant colour in artwork at the museum for the first time in their lives.
“Always concerned with offering the best visitor experience to all audiences, the Centre Pompidou is delighted to offer people with colour blindness the possibility of trying EnChroma glasses, a very innovative device in the museum sector,” said David Cascaro, Director of the Public Division, Centre Pompidou.
While people with normal colour vision see over one million shades and hues of colour, colour blind people see only an estimated 10% of them. To the red-green colour blind, colours appear dull and washed out, with some difficult to distinguish from each other. Common colour confusions include green and yellow, grey and pink, purple and blue, and red and brown. This can detract from the ability of colour blind people to fully experience colourful art.
"We are thrilled that one of the world’s foremost visionaries in arts and culture – the Centre Pompidou – is demonstrating its commitment to accessibility and inclusion for those with colour vision deficiencies by loaning EnChroma glasses to guests," said Erik Ritchie, CEO of EnChroma. “Their example will generate more awareness for the prevalence and effects of colour blindness, inspire other museums and organizations to follow their lead, and ultimately expand opportunities for colour blind people to more fully experience colorful, iconic artwork like never before.”
The Centre Pompidou is the first museum in France to support the needs of colour blind guests via the EnChroma Colour Accessibility Program™. The program already helps colour blind people at nearly 200 public institutions – including libraries, schools, universities, national parks, gardens, tourism bureaus and 80+ major museums – more fully experience colours in art, nature and overcome obstacles to learning. Other museums participating in the program include the Gallerie d’Italia in Italy, the Chau Chak Wing Museum in Australia, Centraal Museum Utrecht in The Netherlands, and the Georgia O’Keeffe Museum, Dallas Museum of Art, and Crystal Bridges Museum of American Art in the US.
Special optical filters in EnChroma glasses help colour blind people perceive a wider range of colours and see them more vividly and distinctly. A study by the University of California, Davis, and INSERM, the French National Institute for Health and Medical Research, demonstrated the effectiveness of EnChroma glasses. A separate recent study in the scientific publication Eye-Nature also highlights the benefits of the glasses.
EnChroma Colour Accessibility Program™
EnChroma is the leading advocate for accessibility for those with colour blindness. The company donates a pair of glasses for every pair an organization purchases. EnChroma also provides materials for institutions to educate the public or teachers, students and parents about colour blindness and its effects. Public organizations interested in the EnChroma Program can email accessibility@enchroma.com.
About the Centre Pompidou
Since 1977, the Centre Pompidou has been deeply rooted in the city of Paris and open to the world and to innovation. Its iconic building is home to Europe's richest and one of the world's largest collections of modern and contemporary art, in addition to exhibitions, symposiums, festivals, shows, projections, and workshops for young people. Its extremely rich programme at the crossroads of art forms and audiences attracts more than 3.5 million visitors every year. True to its ambition to make culture and creation available to as many people as possible, the Centre Pompidou also develops its regional and international presence. For more information, visit: centrepompidou.fr.
About EnChroma
Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Visit enchroma.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213006029/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
Roboverse Reply Impresses at ELROB 2026 With Intelligent Robotic Systems for Critical Missions26.6.2026 10:00:00 CEST | Press release
Roboverse Reply, the Reply Group company specializing in robotics and automation, won the 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial (ELROB) 2026 in Thun, Switzerland. Teaming up with ELP, a specialist for technical equipment for defusing service, the company demonstrated outstanding performance alongside a field of international participants from June 15 to 19, proving that its autonomous solutions operate reliably under real-world conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626012237/en/ Roboverse Reply won 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial 2026, proving that its autonomous solutions operate reliably under real-world conditions. ELROB is Europe’s most demanding and established showcase for robotics and unmanned systems, where leading experts from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
